Considerably, ABL1 is a molecular target for both Imatinib (treating chronic myeloid leukemia) and Mesylate which is in phase I clinical trial for endometrial cancer. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.